Filter zurücksetzen
Stichworte
AML ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

269 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

1. Induction Acute Myeloid Leukemia <=60 years (AML2003) NCT00180102

- 20.09.21 - 1 Formular, 7 Itemgruppen, 37 Datenelemente, 2 Sprachen
Itemgruppen: General Info, Daunorubicin, Ara-C, G-CSF, Cytopenia duration, Transfusions, Signature
AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years http://clinicaltrials.gov/show/NCT00180102 Prospektive, randomisierte, multizentrische Therapieoptimierungsstudie - Studienprotokoll AML2003

Initial assessment Leukemia AML-AZA in elderly patients NCT00915252

- 20.09.21 - 1 Formular, 10 Itemgruppen, 80 Datenelemente, 2 Sprachen
Itemgruppen: Patient data, Clinical findings, Comorbidities, Differential blood count, Clinical Chemistry, Knochenmarkuntersuchung, Zytologie, FAB-Klassifikation, Molekulargenetik, Unterschrift
A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML NCT00915252

2. Induction AML-AZA elderly patients NCT00915252

- 20.09.21 - 1 Formular, 21 Itemgruppen, 88 Datenelemente, 2 Sprachen
Itemgruppen: Patientendaten, Clinical finding, Differential blood count, Klinische Chemie, 5-Azacytidine, 5-Azacytidine - Dose no. 1, 5-Azacytidine - Dose no. 2, 5-Azacytidine - Dose no. 3, 5-Azacytidine - Dose no. 4, 5-Azacytidine - Dose no. 5, 5-Azacytidine dose reduction, Transfusions, Chemotherapy, Ara-C , Daunorubicin, G-CSF, Cytopenia duration, Leukopenia, Neutropenia, Thrombopenia, Unterschrift
2. Induktionstherapieblock EudraCT-Nr 2008-004583-40 Akute myeloische Leukmie(AML) AML alle auer FAB M3 (5-Azacytidin plus Standardtherapie bei älteren AML-Patienten Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA) NCT00915252

Ersterhebung CRF AML2003 AML - Ersterhebung

- 20.09.21 - 1 Formular, 5 Itemgruppen, 23 Datenelemente, 2 Sprachen
Itemgruppen: Allgemeine Angaben, Patientendaten, Klinischer Befund, Randomization, Unterschrift
Prospektive, randomisierte, multizentrische Therapie optimierungsstudie - Studienprotokoll AML2003

consolidation therapy 2 AML in elderly patients AML-AZA NCT00915252

- 20.09.21 - 1 Formular, 21 Itemgruppen, 85 Datenelemente, 2 Sprachen
Itemgruppen: Patientendaten, Clinical finding, Differentialblutbild, Clinical Chemistry, 5-Azacytidine, 5-Azacytidine , 5-Azacytidine - Dose no. 1, 5-Azacytidine - Dose no. 2, 5-Azacytidine - Dose no. 3, 5-Azacytidine - Dose no. 4, 5-Azacytidine - Dose no. 5, 5-Azacytidine dose reduction, Transfusions, Chemotherapy, Ara-C, G-CSF, Cytopenia duration, leukopenia, neutropenia, thrombopenia, Unterschrift
2. Konsolidierungstherapieblock EudraCT-Nr 2008-004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3 consolidation therapy 2 AML in elderly patients AML-AZA NCT00915252 A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML

AML Material Submission Form Pathology NCT00049517 - Material Submission Form Pathology AML E1900 NCT00049517

- 20.09.21 - 1 Formular, 3 Itemgruppen, 31 Datenelemente, 1 Sprache
Itemgruppen: Header, Completed by submitting institutions, Completed by central lab
E1900 Material Submission Form Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia NCT00049517 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A727E0B4-B257-2F80-E034-0003BA0B1A09

Treatment Form - Allogeneic Transplant NCT00049517

- 20.09.21 - 1 Formular, 8 Itemgruppen, 33 Datenelemente, 1 Sprache
Itemgruppen: ECOG clinical trial administrative data, Vital Status, Transplant Conditioning Regimen, Donor Information, Allogeneic Transplant, Transfusions, Comments, CCRR MODULE
Treatment Form - Allogeneic Transplant NCT00049517 Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A727E9EC-B147-2F86-E034-0003BA0B1A09

1. Induktionstherapieblock EudraCT-Nr 2008-004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3 - 1. Induktionstherapieblock

- 20.09.21 - 1 Formular, 17 Itemgruppen, 69 Datenelemente, 2 Sprachen
Itemgruppen: Patientendaten, 5-Azacytidine - Dose no. 1, 5-Azacytidine - Dose no. 2, 5-Azacytidine - Dose no. 3, 5-Azacytidine - Dose no. 4, 5-Azacytidine - Dose no. 5, 5-Azacytidine dose reduction, Differentialblutbild, Chemotherapy, Ara-C , Daunorubicin, G-CSF, Cytopenia duration, leukopenia, neutropenia, thrombopenia, Unterschrift
A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML

1. Konsolidierungstherapieblock EudraCT-Nr 2008-004583-40 Akute myeloische Leukämie(AML) AML alle außer FAB M3 - 1. Konsolidierungstherapieblock

- 20.09.21 - 1 Formular, 15 Itemgruppen, 84 Datenelemente, 2 Sprachen
Itemgruppen: Clinical finding, Differential blood count, Klinische Chemie, 5-Azacytidine, 5-Azacytidine - Dose, 5-Azacytidine dose reduction, Transfusions, Chemotherapy, Ara-C, G-CSF, Cytopenia duration, Leukopenia, Neutropenia, Thrombopenia, Signature
A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML

Leukemia NCT00085124 Registration - CALGB 10201 REGISTRATION WORKSHEET - 2076520v3.0 - CALGB 10201 REGISTRATION WORKSHEET

- 20.09.21 - 1 Formular, 7 Itemgruppen, 35 Datenelemente, 1 Sprache
Itemgruppen: Protocol Administration, Patient Demographics/Pre-Treatment Characteristics, Certification Of Eligibility, Protocol Design, Initial Patient Consent For Specimen Use, Registration Information, CCRR MODULE
CALGB 10201 REGISTRATION WORKSHEET Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B228B8A4-E2DC-4D1A-E034-0003BA12F5E7

DEM

- 20.09.21 - 1 Formular, 1 Itemgruppe, 10 Datenelemente, 1 Sprache
Itemgruppe: Patient demographics
DEM Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF1A18C7-58B3-19A7-E034-0003BA3F9857

Leukemia, Myelocytic, Acute null - - CTEP Transplant CDEs - 2444533v1.0 - CTEP Transplant CDEs

- 20.09.21 - 1 Formular, 1 Itemgruppe, 131 Datenelemente, 1 Sprache
Itemgruppe: Transplantation
CTEP Transplant CDEs Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0B976B1B-4AB1-64EE-E044-0003BA3F9857

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video